Sanofi: in talks for Covid-19 vaccine in EU
(CercleFinance.com) - Sanofi and GSK announce that they have concluded discussions with the European Commission for the supply of up to 300 million doses of a Covid-19 vaccine under a contractual framework for the purchase of doses on behalf of all EU Member States.
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology that Sanofi used to produce an influenza vaccine and on the adjuvant for pandemic use developed by GSK.
The doses would be produced in European countries, including France, Belgium, Germany and Italy. Both health groups are committed to making their Covid-19 vaccine available at an affordable price worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology that Sanofi used to produce an influenza vaccine and on the adjuvant for pandemic use developed by GSK.
The doses would be produced in European countries, including France, Belgium, Germany and Italy. Both health groups are committed to making their Covid-19 vaccine available at an affordable price worldwide.
Copyright (c) 2020 CercleFinance.com. All rights reserved.